The role of alpha2-adrenergic receptors in bone remodeling.
Completed
- Conditions
- Osteoporosis1001329610005959
- Registration Number
- NL-OMON37196
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Age: 18-70 years
Exclusion Criteria
- Hypersensitivity to the active substrate or to any of the excipients
- Severe bradycardia, like sick sinus syndrome and a second or third degree atrioventricular block
- Use of antihypertensive drugs (including diuretics)
- Use of drugs with negative effects on heart rhythm
- Any medication or disease influencing bone turnover
- Inability to give informed consent
- RR < 110/70 mmHg at the start of the experiment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the change in serum concentrations of collagen type<br /><br>1 cross-linked C-telopeptide (CTX) on the intervention and on the control day. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary objective is the change in catecholamine levels and serum<br /><br>concentration of another bone turnover marker, procollagen type I N propeptide<br /><br>(P1NP) on the intervention day (clonidine 0.3mg) and on the control day (no<br /><br>intervention).<br /><br>We will also investigate whether osteoclasts are responsive to the<br /><br>alpha2-adrenoceptor agonist clonidine in vitro, by measuring osteoclast<br /><br>activity and formation.</p><br>